Abstract： Objective:To investigate the effects of alprostadil combined with rat nerve growth factor on serum homocysteine(Hcy), high-sensitivity C-reactive protein(hs-CRP)and antioxidant capacity in patients with type 2 diabetic neuropathy.Methods:A retrospective study was performed on 128 patients with type 2 diabetic neuropathy who were admitted from April 2016 to April 2019, 75 males and 53 females, aged(61.13±8.92)years, and the age range was 34 to 78 years.The patients were divided into alprostadil group( n=37), rat nerve growth factor group( n=42), and combined treatment group( n=49)according to different medication methods.Three groups of patients were treated with Toronto peripheral neuropathy score(TCSS )and visual simulation score(VAS); the sensory(SCV)and motor potential(MCV)of the median, tibial, and gastrocnemius nerves were measured using a full-function evoked potentiometer; Hcy, hs-CRP and antioxidant indicators malondialdehyde and superoxide dismutase(SOD)levels. Results:After treatment, the TCSS and VAS of the combined treatment group[(3.15±0.84)points, (1.35±1.09)points]were significantly lower than those of the alprostadil group[(7.05±1.13)points, (2.13±0.42)points], and the rat nerve Growth factor group[(6.82±1.27)points, (2.05±0.36)points]; SCV in median nerve, tibia nerve, and lower gastrocnemius nerve of the combined treatment group[(49.31±4.15)m/s, (49.15±4.03)m/s, (55.09 4.28)m/s], MCV[(57.84±4.75)m/s, (47.85±4.13)m/s, (48.29±4.35)m/s]were all higher than the alprostadil group[(45.81±3.71)m/s, (45.95±3.88)m/s, (44.07±3.69)m/s, (48.08±4.58)m/s, (39.14±3.04)m/s, (41.04±3.88)m/s]and rat nerve growth factor group[(44.92±3.59)m/s, (48.08±3.92)m/s, (49.27±4.12)m/s, (54.92±4.61)m/s, (43.55±3.92)m/s, (44.27±3.69)m/s]; Hcy, hs-CRP, malondialdehyde, and SOD levels in the combined treatment group[(18.73±3.62)μmol/L, (6.21±1.06)mg/L, (4.09±0.62)mmol/ml, (55.77±28.83)nU/ml]are significantly lower than the alprostadil group[(21.09±3.88)μmol/L, (9.52±1.14)mg/L, 6.01±0.85)mmol/ml, (76.17±30.05)nU/ml]and rat nerve growth factor group[(22.27±4.14)μmol/L, (10.04±1.39)mg/L, (6.14±0.88)mmol/ml, (78.34 ± 29.91)nU/ml], the difference was statistically significant( P<0.05). Conclusion:Alprostadil combined with mouse nerve growth factor has a better effect on the remission of type 2 diabetic neuropathy, and the effect of combined treatment is significantly better than that of single drug, which is worthy of reference in clinical practice.